amfetamine/ guanfacine / Genco Sci - LARVOL DELTA

CA09 – Advancing the understanding of treatment discontinuity in adult ADHD using real-world data (ECNP 2023) - "Increasing use of ADHD medications, newly available therapeutic options (e.g., lisdexamfetamine, guanfacine), and growing number of adults, in particular females, being considered for treatment, may have affected patterns of medication discontinuation and persistence in ADHD. Therefore, up-to-date evidence on the scope of treatment discontinuation across the lifespan and from multiple geographical regions is needed."

Clinical • Real-world • Real-world evidence • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Advancing the understanding of treatment discontinuity in adult ADHD using real-world data (ECNP 2023) - "Increasing use of ADHD medications, newly available therapeutic options (e.g., lisdexamfetamine, guanfacine), and growing number of adults, in particular females, being considered for treatment, may have affected patterns of medication discontinuation and persistence in ADHD. Therefore, up-to-date evidence on the scope of treatment discontinuation across the lifespan and from multiple geographical regions is needed."

Clinical • Real-world • Real-world evidence • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010-2019. (PubMed, Eur J Clin Pharmacol) - "ADHD medication use during pregnancy increased in Norway and Sweden in the last decade. However, discontinuation rates during pregnancy were high. Those who used ADHD medication had more risk factors for pregnancy complications including low parity, smoking, and other psychotropic drug use."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Patterns of attention deficit hyperactivity disorder medicine use in the era of new non-stimulant medicines: A population-based study among Australian children and adults (2013-2020). (PubMed, Aust N Z J Psychiatry) - "New therapeutic options such as lisdexamfetamine and guanfacine have recently become available for the treatment of attention deficit hyperactivity disorder. Poor long-term treatment persistence in adolescence may warrant improved clinical monitoring of attention deficit hyperactivity disorder in patients transitioning from paediatric to adult care. Reassuringly, use of newly approved guanfacine appeared to be in accordance with guidelines among children."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Pediatrics • Psychiatry

First-Time Users of ADHD Medication Among Children and Adolescents in Germany: An Evaluation of Adherence to Prescribing Guidelines Based on Claims Data. (PubMed, Front Psychiatry) - "Most of the ADHD drug users received first-line ADHD pharmacotherapy (methylphenidate, atomoxetine), whereas 2.6% were prescribed second-line ADHD medication (lisdexamfetamine, guanfacine, dexamfetamine, multiple ADHD drugs) as first drug. Off-label prescribing regarding drug choice and age of patients only occurred in a small percentage of initial pharmacological ADHD treatment. Our results suggest the need for improvement in rational prescribing, especially with regard to diagnostic requirements."

Clinical • Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mental Retardation • Pediatrics • Psychiatry

Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis. (PubMed, PLoS One) - "Overall, despite a class effect of improving clinical response relative to placebo, there were few differences among the individual ADHD pharmacotherapies, and most studies were at risk of at least one important source of bias. Furthermore, the certainty of the evidence was very low to low for all outcomes, and there was limited reporting of long-term adverse events. As such, the choice between ADHD pharmacotherapies may depend on individual patient considerations, and future studies should assess the long-term effects of individual pharmacotherapies on patient-important outcomes, including quality of life, in robust blinded RCTs."

Journal • Retrospective data • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Psychiatry